Lilly expands access to its experimental obesity therapy while Jazz pulls Zepzelca's second-line lung cancer use

Lilly announced it will broaden the expanded‑access program for its obesity drug that has not yet received regulatory approval, allowing more patients to receive the treatment under a compassionate‑use framework.

The company said the move reflects strong demand for new obesity options and will help collect additional safety and efficacy data as the product moves toward potential approval.

Jazz Pharmaceuticals disclosed that it is withdrawing the second‑line indication of Zepzelca for small cell lung cancer, removing that use from its product label.

The withdrawal indicates Jazz is refocusing its development efforts after reviewing clinical outcomes for the indication.